Table 1. Patient baseline characteristics.
Lenalidomide (n = 21) | Lenalidomide plus cetuximab (n = 29) | ||
Median age, years (range) | 54 (38–75) | 58 (31–70) | |
Sex | Male | 12 (57.1%) | 16 (55.2%) |
Female | 9 (42.9%) | 13 (44.8%) | |
ECOG PS score | 0 | 10 (47.6%) | 20 (69.0%) |
1 | 10 (47.6%) | 9 (31.0%) | |
2 | 1 (4.8%) | 0 | |
Concomitant steroids | 7 (33%) | 12 (41%) | |
Previous lines of systemic anticancer therapy | 2 | 5 (23.8%) | 9 (31.0%) |
3 | 4 (19.0%) | 6 (20.7%) | |
>3 | 12 (57.1%) | 14 (48.2%) |
ECOG PS, Eastern Cooperative Oncology Group performance status.